423 related articles for article (PubMed ID: 10757057)
1. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
2. Recombinant immunotoxins for cancer therapy.
Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P
Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
4. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
6. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
7. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
8. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
9. Recombinant toxins for the treatment of cancer.
Kreitman RJ
Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
[TBL] [Abstract][Full Text] [Related]
10. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
[TBL] [Abstract][Full Text] [Related]
12. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
14. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
Chiron MF
Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
16. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
17. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins: protein engineering for cancer therapy.
Brinkmann U
Mol Med Today; 1996 Oct; 2(10):439-46. PubMed ID: 8897439
[TBL] [Abstract][Full Text] [Related]
19. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
20. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]